Kairos Pharma (KAPA) Total Non-Current Liabilities (2023 - 2024)
Kairos Pharma's (KAPA) quarterly Total Non-Current Liabilities came in at $992000.0 in Q4 2024, down 67.36% YoY from $3.0 million in Q1 2024, and down 40.67% on a QoQ basis from $1.7 million in Q3 2024.
Kairos Pharma (KAPA) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Kairos Pharma (KAPA) has 2 years of Total Non-Current Liabilities data on file, last reported at $992000.0 in Q4 2024.
- Quarterly Total Non-Current Liabilities fell 67.36% year-over-year to $992000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $992000.0 (down 67.36% YoY) and the FY2024 annual result came in at $992000.0, down 67.36% from the prior year.
- Total Non-Current Liabilities fell to $992000.0 in Q4 2024, from $1.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.0 million in Q4 2023 to a low of $992000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 992,000.00 |
| Sep 30, 2024 | 1.67 Mn |
| Dec 31, 2023 | 3.04 Mn |